Search
Multiple Sclerosis Clinical Trials in Rochester, NY
A listing of 4 Multiple Sclerosis clinical trials in Rochester, NY actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 4 of 4
The city of Rochester, New York, currently has 4 active clinical trials seeking participants for Multiple Sclerosis research studies.
Featured Trial
Secondary Progressive Multiple Sclerosis Study
Recruiting
Conditions:
Multiple Sclerosis(MS)
Secondary Progressive Multiple Sclerosis
Featured Trial
Relapsing Multiple Sclerosis Study
Recruiting
Conditions:
Multiple Sclerosis(MS)
Relapsing-Remitting Multiple Sclerosis
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Recruiting
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12. At Month 12, participants will be randomized (1:1:1) to one of three Arms with randomized treatm... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/13/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/22/2024
Locations: Novartis Investigative Site, Rochester, New York
Conditions: Multiple Sclerosis
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Recruiting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.
The TRaditional versus Ear... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Multiple Sclerosis, Relapsing-Remitting
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.
All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/26/2024
Locations: Rochester Multiple Sclerosis Center, University of Rochester, Rochester, New York
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
1 - 4 of 4